Fairfield Market Research Hyperhidrosis Treatment Market Size, Share, Growth, 2022-2029

Hyperhidrosis Treatment Market

Global Industry Analysis (2018 - 2021) - Growth Trends and Market Forecast (2022 - 2029)

Published Date: Upcoming | Format:

Industry: Pharmaceuticals & Biotechnology

Request TOC Request Customization $4,995.00Prebook

Increased Prevalence of Secondary Hyperhidrosis Drive Growth of Hyperhidrosis Treatment Market

The global hyperhidrosis treatment market is expected to grow significantly over the forecast period due to an increase in secondary hyperhidrosis cases worldwide. Secondary hyperhidrosis is becoming more common as a result of sedentary lifestyles, unhealthy diets, and alcohol habits, which cause a variety of diseased conditions such as hypoglycaemia, hyperthyroidism, and anxiety. Although cases are uncommon, there are several types of secondary hyperhidrosis. For instance, gustatory sweating is a condition in which facial sweating occurs in response to food consumption. Similarly, Frey Syndrome is characterised by abnormal regeneration of damaged parasympathetic fibres that have been destroyed by a parotid or salivary tumour or surgical resection of a tumour.

Treatment adoption will increase due to the high prevalence of primary and secondary hyperhidrosis. According to a research report titled "Hyperhidrosis" released in October 2021 in the United States National Library of Medicine, it affects roughly 3% of the US population and is most common in people aged 20 to 60. The high incidence has resulted in a 20% increase in the use of over-the-counter aluminium chloride hexahydrate in the country. As a result of its predominance, product consumer demand will rise, resulting in market expansion.

To establish a strong presence and expand their geographical reach, market players use inorganic and organic strategies such as expansions, product launches, acquisitions, collaborations, mergers, and partnerships. For instance, in April 2021, Fortress Biotech and its partner company Journey Medical entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, an Eli Lilly wholly-owned subsidiary. Similarly, BOTOX, manufactured by Allergan Inc, is the most researched botulinum toxin in the world. Some of the medications under clinical trials for the treatment of hyperhidrosis include Revance Therapeutics Inc's RT002 and Brickell Biotech Inc's Sofpironium Bromide, a topical anticholinergic. As a result of these factors, the studied market is expected to grow.

Long-Lasting Effects of Botulinum Toxin A to Enhance Hyperhidrosis Treatment Growth

Botox's effectiveness in treating hyperhidrosis, as well as its long-lasting effects, are driving the market growth. Botulinum toxin type A is a non-invasive surgical treatment for focal hyperhidrosis that lasts longer than topical treatments. Injections of botulinum toxin are most commonly used to treat axillary hyperhidrosis, but they can also be used to treat palmar and plantar disease. Botulinum toxin's effects last six to nine months on average, and treatment is associated with a high level of patient satisfaction. Botulinum toxin A can be used to treat excessive sweating in the armpits, hands, feet, head and face (craniofacial), and other small body areas (such as under the breasts).

Increasing Primary Hyperhidrosis Burden to Drive Growth of North American Hyperhidrosis Treatment Market

North America is expected to dominate the overall hyperhidrosis treatment market over the forecast period. The major factors contributing to its high share include increased hyperhidrosis diagnosis rates, as well as the availability of technologically advanced and sophisticated treatment options. Increasing primary hyperhidrosis burden, cancer, and cardiovascular disorders, which increase secondary hyperhidrosis, technological advancements, and the presence of key market players in the region.

Within North America, the United States has a sizeable share of the hyperhidrosis treatment market. The availability of public and private research funds, as well as the presence of key market players in the region, a growing focus on precision medicine, and rising awareness about the availability of safer medicines are among the key factors driving the market growth for Hyperhidrosis Treatment in this region. For instance, updates to commercialise QBREXZA (glycopyrronium) cloth, an anticholinergic intended for the topical treatment of primary axillary hyperhidrosis in adult and paediatric patients, have been announced by companies including Dermira, Inc.

Furthermore, increased research and development activities for hyperhidrosis treatment products in the United States are likely to lead to increased adoption of these products, driving the market's growth in the United States. According to the article "Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomised controlled trials" published in the Journal of the American Academy of Dermatology in January 2019, Glycopyrronium tosylate (GT) applied topically on a daily basis over 4 weeks reduced sweating severity as measured by ASDD-Item 2, sweat production as measured gravimetrically, and was generally well tolerated. Such initiatives increase the number of innovative products on the market, which boosts future market growth.

Global Hyperhidrosis Treatment Market: Competitive Landscape

Companies in the hyperhidrosis treatment market are introducing new products alongside initiation collaborations, alliances and partnership agreements. For instance, in October 2021, the Phase 3 pivotal Cardigan I and Cardigan II studies, assessed sofpironium bromide gel, 15% as a once-daily topical application in patients with primary axillary hyperhidrosis, and reported positive topline results. On the other hand, in April 2021, Fortress Biotech, a Journey Medicals partner company, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, an Eli Lilly wholly-owned subsidiary.

A few of the players in the hyperhidrosis treatment market include Brickell Biotech, Inc., Sientra, Inc., Revance Therapeutics, Inc., AbbVie, Inc., Allergan, Inc., Brickell Biotech, Inc., Dermira, Inc, GlaxoSmithKline plc, Ulthera, Inc. and TheraVida, Inc.

Global Hyperhidrosis Treatment Market is Segmented as Below:

By Treatment Type

  • Botulinum Toxin A
  • Laser Treatments
  • Surgical Treatments
  • Topical Treatments
  • Others

By Disease Type

  • Primary Focal Hyperhidrosis
  • Secondary Generalised Hyperhidrosis

By End-user

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • South Korea
    • India
    • China
    • Rest of Asia-Pacific
    • Latin America
    • Middle East
    • Africa

Key Elements Included In The Study: Global Hyperhidrosis Treatment Market

  • Hyperhidrosis Treatment Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 - 2021
  • Market Value at Regional and Country Level, 2022 - 2029
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2022 - 2029
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.


  • The segmentation/company profiles/countries depicted above may vary in the actual report.

Request Table of Contents

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services